BIOMAT Database Logo BIOMAT Database Logo

Trandolapril in Cushing's disease: short-term trandolapril treatment in patients with Cushing's disease and essential hypertension. 1998

S Zacharieva, and S Torbova, and M Orbetzova, and J Vergilova, and E Nachev, and M Wippermann, and L Baurenski, and P Angelova-Gateva, and D Tzingilev
Clinical Centre of Endocrinology and Gerontology, Medical University, Sofia, Bulgaria.

A study was performed on seven patients with Cushing's disease and seven age and sex matched patients with essential hypertension. The patients maintained their usual diet and sodium intake and received the ACE inhibitor trandolapril at a dose of 2 mg daily for 8 days. Trandolapril treatment resulted in an increase in the active renin and decrease in the urinary kallikrein activity in both study groups. Blood pressure decreased significantly in patients with Cushing's disease and essential hypertension after 8 days of trandolapril treatment. The opposite responses of renin and kallikrein to ACE inhibition support a possible feed-back mechanism of regulation between the renin-angiotensin system and the kallikrein-kinin system.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007211 Indoles Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
D007610 Kallikreins Proteolytic enzymes from the serine endopeptidase family found in normal blood and urine. Specifically, Kallikreins are potent vasodilators and hypotensives and increase vascular permeability and affect smooth muscle. They act as infertility agents in men. Three forms are recognized, PLASMA KALLIKREIN (EC 3.4.21.34), TISSUE KALLIKREIN (EC 3.4.21.35), and PROSTATE-SPECIFIC ANTIGEN (EC 3.4.21.77). Kallikrein,Kininogenase,Callicrein,Dilminal,Kallidinogenase,Kalliginogenase,Kallikrein A,Kallikrein B',Kallikrein Light Chain,Kinin-Forming Enzyme,Padutin,alpha-Kallikrein,beta-Kallikrein,beta-Kallikrein B,Enzyme, Kinin-Forming,Kinin Forming Enzyme,Light Chain, Kallikrein,alpha Kallikrein,beta Kallikrein,beta Kallikrein B
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D003480 Cushing Syndrome A condition caused by prolonged exposure to excess levels of cortisol (HYDROCORTISONE) or other GLUCOCORTICOIDS from endogenous or exogenous sources. It is characterized by upper body OBESITY; OSTEOPOROSIS; HYPERTENSION; DIABETES MELLITUS; HIRSUTISM; AMENORRHEA; and excess body fluid. Endogenous Cushing syndrome or spontaneous hypercortisolism is divided into two groups, those due to an excess of ADRENOCORTICOTROPIN and those that are ACTH-independent. Cushing's Syndrome,Hypercortisolism,Syndrome, Cushing,Syndrome, Cushing's
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

S Zacharieva, and S Torbova, and M Orbetzova, and J Vergilova, and E Nachev, and M Wippermann, and L Baurenski, and P Angelova-Gateva, and D Tzingilev
Effect of short-term losartan treatment in patients with primary aldosteronism and essential hypertension.
April 2001, Methods and findings in experimental and clinical pharmacology,
S Zacharieva, and S Torbova, and M Orbetzova, and J Vergilova, and E Nachev, and M Wippermann, and L Baurenski, and P Angelova-Gateva, and D Tzingilev
Ocular and orbital blood flow in patients with essential hypertension treated with trandolapril.
January 1998, Retina (Philadelphia, Pa.),
S Zacharieva, and S Torbova, and M Orbetzova, and J Vergilova, and E Nachev, and M Wippermann, and L Baurenski, and P Angelova-Gateva, and D Tzingilev
Effects of the converting enzyme inhibitor trandolapril on short-term variability of blood pressure in essential hypertension.
December 1991, Clinical autonomic research : official journal of the Clinical Autonomic Research Society,
S Zacharieva, and S Torbova, and M Orbetzova, and J Vergilova, and E Nachev, and M Wippermann, and L Baurenski, and P Angelova-Gateva, and D Tzingilev
Trandolapril in patients with essential hypertension: effects on vascular and cardiac structural changes.
January 1994, Journal of cardiovascular pharmacology,
S Zacharieva, and S Torbova, and M Orbetzova, and J Vergilova, and E Nachev, and M Wippermann, and L Baurenski, and P Angelova-Gateva, and D Tzingilev
Haemodynamic effects of short-term treatment with bopindolol in essential hypertension.
January 1988, European journal of clinical pharmacology,
S Zacharieva, and S Torbova, and M Orbetzova, and J Vergilova, and E Nachev, and M Wippermann, and L Baurenski, and P Angelova-Gateva, and D Tzingilev
Short and long term treatment of essential hypertension with felodipine as monotherapy.
January 1987, Drugs,
S Zacharieva, and S Torbova, and M Orbetzova, and J Vergilova, and E Nachev, and M Wippermann, and L Baurenski, and P Angelova-Gateva, and D Tzingilev
Volumetric magnetic resonance imaging analysis in patients with short-term remission of Cushing's disease.
October 2017, Clinical endocrinology,
S Zacharieva, and S Torbova, and M Orbetzova, and J Vergilova, and E Nachev, and M Wippermann, and L Baurenski, and P Angelova-Gateva, and D Tzingilev
Cardiovascular effects of a trandolapril/verapamil combination in patients with mild to moderate essential hypertension.
March 1997, The American journal of cardiology,
S Zacharieva, and S Torbova, and M Orbetzova, and J Vergilova, and E Nachev, and M Wippermann, and L Baurenski, and P Angelova-Gateva, and D Tzingilev
[Ambulatory treatment of so-called "essential" arterial hypertension with pindolol. Short-term study].
January 1980, Minerva medica,
S Zacharieva, and S Torbova, and M Orbetzova, and J Vergilova, and E Nachev, and M Wippermann, and L Baurenski, and P Angelova-Gateva, and D Tzingilev
Short- and long-term effects of spirapril on renal hemodynamics in patients with essential hypertension.
April 1993, Journal of clinical pharmacology,
Copied contents to your clipboard!